Centaurus Financial Inc. purchased a new stake in shares of Cerevel Therapeutics during the first quarter worth about $105,000.

Source: https://www.etfdailynews.com/2023/08/09/cerevel-therapeutics-nasdaqcere-shares-gap-up-on-insider-buying-activity/

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.

Source: https://www.americanbankingnews.com/2023/08/03/cerevel-therapeutics-nasdaqcere-price-target-lowered-to-41-00-at-hc-wainwright.html

Cerevel Therapeutics Holdings, Inc. ()’s share price gapped up prior to trading on Tuesday after an insider bought additional shares in the company.

Source: https://www.etfdailynews.com/2023/08/09/cerevel-therapeutics-nasdaqcere-shares-gap-up-on-insider-buying-activity/

Finally, Piper Sandler reiterated a neutral rating and issued a $45.00 target price (up from $33.00) on shares of Cerevel Therapeutics in a research report on Thursday.

Source: https://www.dailypolitical.com/2023/12/10/cerevel-therapeutics-nasdaqcere-downgraded-by-hc-wainwright.html

In other news, CEO N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock in a transaction on Thursday, June 1st.

Source: https://www.americanbankingnews.com/2023/08/03/cerevel-therapeutics-nasdaqcere-price-target-lowered-to-41-00-at-hc-wainwright.html

Mizuho decreased their target price on shares of Cerevel Therapeutics from $29.00 to $25.00 and set a “neutral” rating for the company in a research report on Monday.

Source: https://www.etfdailynews.com/2023/08/09/cerevel-therapeutics-nasdaqcere-shares-gap-up-on-insider-buying-activity/

Piper Sandler initiated coverage on shares of Cerevel Therapeutics ( in a research report report published on Wednesday morning, reports.

Source: https://www.etfdailynews.com/2023/10/01/cerevel-therapeutics-nasdaqcere-coverage-initiated-at-piper-sandler/